Naringin nanoparticles alleviate RA-ILD pulmonary fibrosis by targeting 14-3-3ζ to inhibit LYVE1+ macrophages TGF-β1 secretion - PubMed
6 hours ago
- #Pulmonary fibrosis
- #RA-ILD
- #Naringin nanoparticles
- Naringin nanoparticles (NAR) show potential in treating RA-ILD pulmonary fibrosis by targeting 14-3-3ζ to inhibit TGF-β1 secretion from LYVE1+ macrophages.
- Transcriptome analysis identified NAR as a potential treatment, leading to the development of NAR nanoparticles tested on a CIA-ILD mouse model.
- NAR nanoparticles significantly reduced pulmonary fibrosis in mice and increased LYVE1+ macrophages in lung tissue.
- Mechanistically, NAR targets 14-3-3 zeta to increase LYVE1 levels in macrophages, inhibiting epithelial-mesenchymal and fibroblast-myofibroblast transitions.
- The study suggests NAR as a novel therapeutic option for RA-ILD, highlighting LYVE1+ macrophages as a potential target for drug development.